The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors
Open accessAbstract
High Resolution Image Download MS PowerPoint Slide Hyperactivation of mTOR kinase by mutations in the PI3K/mTOR pathway or by crosstalk with other mutant cancer drivers, such as RAS, is a feature of many tumors. Multiple allosteric inhibitors of mTORC1 and orthosteric dual inhibitors of mTORC1 and mTORC2 have been developed as anticancer drugs, but their clinical utility has been limited. To address these limitations, we have developed a novel class of “bi-steric inhibitors” that interact with both the orthosteric and the allosteric binding sites in order to deepen the inhibition of mTORC1 while also preserving selectivity for mTORC1 over mTORC2. In this report, we describe the discovery and preclinical profile of the development candidate RMC-5552 and the in vivo preclinical tool compound RMC-6272. We also present evidence that selective inhibition of mTORC1 in combination with covalent inhibition of KRAS G12C shows increased antitumor activity in a preclinical model of KRAS G12C mutant NSCLC that exhibits resistance to KRAS G12C inhibitor monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







![Figure 5 (A) Local resolution map of the mTORC1-RMC-5552-FKBP12 cryo-EM structure (PDB 8ERA). Higher resolution core of the map allows for confident modeling of side chains and both the rapalog-like and the ATP-competitive moieties of RMC-5552. N-HEAT domain of mTOR (right) and WD40 domain of Raptor (left) are more disordered than other regions of the map and consequently approach 7 Å. (B) Cryo-EM map of mTORC1-FKBP12-RMC-5552 38 complex. mTORC1-FKBP12-RMC-5552 38 complex cryo-EM map is shown colored by protomer. Blue is mTOR, green is Raptor, purple is mLST8, and red is FKBP12. (C) Cryo-EM map reveals density for rapalog moiety of RMC-5552 38 binding at its expected location between FKBP12 and the FRB domain at threshold 0.0033. (D) Cryo-EM map reveals density corresponding to the ATP-competitive moiety of RMC-5552 38 (orange) binding mTOR (blue) at its orthosteric site at threshold 0.024. Multiple hydrogen bonds are formed between mTOR and ligand, including with mTOR residues K2187, E2190, G2238, and V2240 (black dashed lines). 4-Aminopyrazolo[3,4-d]pyrimidine core of RMC-5552 π stacks with the aromatic side chain of mTOR residue W2239 (purple dashed line). Density (gray transparent surface) does not extend beyond the beginning of the linker region.](https://figures.cochat.ai/paper-figures/fa7711cac0f845929c9c0e9597ecfc74/discovery-of-rmc-5552-a-selective-bi-steric-inhibitor-of-mtorc1-for-the-figure-5.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991) · Cell · doi:10.1016/0092-8674(91)90124-h · Cited by 4,116
Kim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,114
A mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053
Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast
Heitman, J., Movva, N. R., & Hall, M. N. (1991) · Science · doi:10.1126/science.1715094 · Cited by 2,006
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886
VÉZINA, C., KUDELSKI, A., & SEHGAL, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,687
Research works printed but not linked: 23
- Sehgal, S. N.; Blazekovic, T. M.; Vezina, C. Rapamycin und seine herstellung. Patent application number DE1973-2347682, 1973; Chem Abstr. 1974 , 81 , 24166.
- Sehgal, S. N.; Blazekovic, T. M.; Vézina, C. Rapamycin and process of preparation. U.S. Patent 3,929,992, 1975; Chem Abstr. 1976 , 85 , 3861.
- Sehgal, S. N.; Blazekovic, T. M.; Vezina, C. Rapamycin and process of preparation. U.S. Patent 3,993,749, 1976; Chem Abstr. 1977 , 86 , 41806.
- Sidorowicz, H.; Baker, H.; Vézina, C. Rapamycin (AY-22,989), a new antifungal antibiotic: in vitro and in vivo studies. 15th Interscience Conference on Antimicrobial Agents and Chemotherapy , Sept 24–26, 1975, Washington, DC; American Society for Microbiology, 1975; Abstract 26.
- Morris R. E., 1989, Med. Sci. Res., 17, 609
- aSehgal, S. N.; Vézina, C. Compositions pharmaceutiques à base de rapamycine pour le traitement de tumeurs carcinogens. Patent number BE877700, 1980; Chem Abstr. 1980 , 93 , 88940. See also.
- Eng, C. P. Combination of rapamycin and picibanil for the treatment of tumors. U.S. Patent 4,401,653, 1983; Chem Abstr. 1983 , 98 , 22284.
- Shokat, K.; Okaniwa, M. mTORCl inhibitors. WO2016040806, 2016; Chem Abstr. 2016 , 164 , 412316.
- Ren, P.; Liu, Y.; Li, L.; Chan, K.; Wilson, T. E. Benzoxazole kinase inhibitors and methods of use. WO2010051043, 2010; Chem Abstr. 2010 , 152 , 542024.
- Semko, C.; Pitzen, J.; Wang, G.; Tibrewal, N.; Aggen, J. B.; Thottumkara, A. P.; Burnett, G. L.; Gliedt, M. J. E.; Kiss, G.; Won, W.; Lee, J. C.; Gill, A. L. Rapamycin analogs as mTOR inhibitors. WO2018204416, 2018; Chem Abstr. 2018 , 169 , 525729.
- Pitzen, J.; Gliedt, M. J. E.; Burnett, G. L.; Aggen, J. B.; Kiss, G.; Cregg, J. J.; Semko, C. M.; Won, W.; Wang, G.; Lee, J. C-L.; Thottumkara, A. P.; Gill, A. L.; Mellem, K. T. C40- C28- and C32-linked rapamycin analogs as mTOR inhibitors. WO2019212990, 2019; Chem Abstr. 2019 , 171 , 558403.
- Semko, C. M.; Wang, G.; Burnett, G. L.; Aggen, J. B.; Kiss, G.; Cregg, J. J.; Gliedt, M. J. E.; Pitzen, J.; Lee, J. C-L.; Won, W.; Thottumkara, A. P.; Gill, A. L. C26-linked rapamycin analogs as mTOR inhibitors. WO2019212991, 2019; Chem Abstr. 2019 , 171 , 551179.
- Mahauad-Fernandez, W. D.; Yang, Y. C.; Lai, I.; Park, J.; Yao, L.; Evans, J. W.; Burnett, L. G.; Gill, A.; Smith, J. A. M.; Singh, M.; Felsher, D. W. Bi-steric mTORC1-selective Inhibitors activate 4EBP1 reversing MYC-induced tumorigenesis and synergize with immunotherapy; https://www.biorxiv.org/content/10.1101/2022.02.04.478208v1. · doi:10.1101/2022.02.04.478208v1
- Tibrewal N., 2018, Proceedings of the AACR Special Conference on Targeting PI3K/mTOR Signaling
- Yang Y. C., 2020, Proceedings of the Annual Meeting of the American Association for Cancer Research 2020, Virtual Meeting II
- Burnett G. L., 2021, Proceedings of the Annual Meeting of the American Association for Cancer Research 2021, Virtual Meeting I
- Mahauad-Fernandez W., 2021, Proceedings of the Annual Meeting of the American Association for Cancer Research 2021, Virtual Meeting I
- Du H., 2021, Proceedings of the Annual Meeting of the American Association for Cancer Research 2021, Virtual Meeting I
- Cottens, S.; Sedrani, R. O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants. WO9409010, 1994; Chem Abstr. 1994 , 122 , 9774.
- Hu, D. C. Preparation of rapamycin carbonate esters as immunosuppressant agents. U.S. Patent 5,260,300, 1993; Chem Abstr. 1993 , 120 , 269937.
- Nelson, F. C. 27-hydroxyrapamycin and derivatives thereof. U.S. Patent 5,256790, 1993; Chem Abstr. 1993 , 121 , 9034.
- Cottens, S.; Sedrani, R. Synthesis and immunosuppressant activity of rapamycin derivatives. WO9641807, 1996; Chem Abstr. 1996 , 126 , 157342.
- Zhu, T. Oxepane isomer of 42-O-(2-hydroxyethyl)rapamycin. U.S. Patent 7,241,771, 2007; Chem Abstr. 2006 , 145 , 292763.
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer
Hao, C., Wei, Y., Meng, W., Zhang, J., & Yang, X. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102861 · Cited by 99
μMap Photoproximity Labeling Enables Small Molecule Binding Site Mapping
Huth, S. W., Oakley, J. V., Seath, C. P., Geri, J. B., Trowbridge, A., Parker, D. L., Rodriguez‐Rivera, F. P., Schwaid, A. G., Ramil, C. P., Ryu, K. A., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c03325 · Cited by 78
PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities
Wiese, W., Barczuk, J., Racińska, O., Siwecka, N., Rozpędek‐Kamińska, W., Słupianek, A., Sierpiński, R., & Majsterek, I. (2023) · Cancers · doi:10.3390/cancers15215297 · Cited by 87
Teng, M., & Gray, N. S. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.06.020 · Cited by 66
Metadata
- Authors
- Burnett, G. L., Yang, Y. C., Aggen, J. B., Pitzen, J., Gliedt, M. K., Semko, C. M., Marquez, A., Evans, J. W., Wang, G., Won, W. S., Tomlinson, A. C. A., Kiss, G., Tzitzilonis, C., Thottumkara, A. P., Cregg, J., Mellem, K. T., Choi, J. S., Lee, J. C., Zhao, Y., Lee, B. J., Meyerowitz, J. G., Knox, J. E., Jiang, J., Wang, Z., Wildes, D., Wang, Z., Singh, M., Smith, J. A. M., & Gill, A. L.
- Affiliations
- Revolution Medicines (United States) (US)
- Corresponding author
- Burnett, G. Leslie
- Gill, Adrian L.
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2022-12-19
- Volume
- 66
- Issue
- 1
- Pages
- 149-169
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- PMC
- PMC9841523
- OpenAlex
- W4311927080
- Cited by
- 72
- References
- 74
- Citations by year
- 2026: 25 · 2025: 19 · 2024: 11 · 2023: 17
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Medicinal Chemistry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion, cc-by)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- mTORC1 inhibition, PI3K/mTOR pathway, KRAS G12C, non-small cell lung cancer, anticancer drug discovery
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Mechanistic Target of Rapamycin Complex 2, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Proto-Oncogene Proteins p21(ras), Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors. https://app.cochat.ai/papers/10.1021/acs.jmedchem.2c01658
- The paper
- Burnett, G. L., Yang, Y. C., Aggen, J. B., Pitzen, J., Gliedt, M. K., Semko, C. M., Marquez, A., Evans, J. W., Wang, G., Won, W. S., Tomlinson, A. C. A., Kiss, G., Tzitzilonis, C., Thottumkara, A. P., Cregg, J., Mellem, K. T., Choi, J. S., Lee, J. C., Zhao, Y., . . . Gill, A. L. (2023). Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c01658
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.